PHARMAC is aware that five deaths have been reported to the Centre for Adverse Reactions Monitoring (CARM) as potential adverse reactions to the brand change. There is currently no evidence linking the deaths to the brand change. We cannot comment further while the Chief Coroner investigates these deaths.
To reassure people taking lamotrigine, we widened our rules so more people could stay on their current brand of lamotrigine. We are continuing to monitor the situation.
Exceptional circumstances applications
Total received: 1,781
Under assessment: 81
Updated: 15 January 2020